Ibrutinib CAS 936563-96-1 Mimo>99.5% (HPLC) API Aworan Ifihan

Ibrutinib CAS 936563-96-1 Mimọ>99.5% (HPLC) API

Apejuwe kukuru:

Orukọ Kemikali: Ibrutinib

CAS: 936563-96-1

Mimọ:> 99.5% (HPLC)

Irisi: Funfun si Paa-White Crystal Powder

Ibrutinib jẹ oludena BTK ti a lo lati ṣe itọju Aisan lukimia onibaje Lymphocytic (CLL) ati Mantle Cell Lymphoma (MCL)

Olubasọrọ: Dokita Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Fi imeeli ranṣẹ si wa

Alaye ọja

Jẹmọ Products

ọja Tags

Apejuwe:

Awọn agbedemeji ti o jọmọ Ibrutinib:
(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1
4-Phenoxyphenylboronic Acid CAS 51067-38-0
Ibrutinib Intermediate N-2 CAS 330786-24-8
Ibrutinib Intermediate N-3 CAS 330792-70-6
Ibrutinib CAS 936563-96-1

Kemikali Properties:

Orukọ Kemikali	Ibrutinib
Awọn itumọ ọrọ sisọ	1- [(3R) -3- [4-Amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidin-1-yl] -1-piperidinyl]-2-propen-1- ọkan;PCI-32765
Nọmba CAS	936563-96-1
Iṣura Ipo	Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn Toonu
Fọọmu Molecular	C25H24N6O2
Òṣuwọn Molikula	440.50
Brand	Ruifu Kemikali

Awọn pato:

Nkan	Awọn pato
Ifarahan	Funfun to Pa-White Crystal Powder
Idanimọ	IR;HPLC
Pipadanu lori Gbigbe	<0.50%
Aloku lori Iginisonu	≤0.10%
Awọn irin Heavy (gẹgẹbi Pb)	≤20ppm
Eyikeyi Nikan Aimọ	≤0.20%
Lapapọ Awọn Aimọ	<0.50%
Mimọ / Analysis Ọna	> 99.5% (HPLC)
Igbeyewo Standard	Standard Enterprise
Lilo	API

Package & Ibi ipamọ:

Package: Igo, apo apamọwọ Aluminiomu, 25kg / Paali Drum, tabi gẹgẹbi ibeere alabara.

Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina ati ọrinrin.

Awọn anfani:

FAQ:

Ohun elo:

Ibrutinib (CAS: 936563-96-1) jẹ inhibitor ti Bruton tyrosine kinase (BTK) fun itọju ti aisan lukimia onibaje lymphocytic (CLL) ati lymphoma mantle cell (MCL).Mejeeji MCL ati CLL jẹ ti sẹẹli B-cell ti kii-Hodgkin's lymphoma, eyiti o jẹ itusilẹ ati itara si ifasẹyin.Kimoterapi ti o wọpọ ko ni ìfọkànsí, ati ite 3 tabi 4 awọn aati ikolu nigbagbogbo waye.Ibrutinib le darapọ pẹlu BTK, eyiti o jẹ pataki fun dida, iyatọ, ibaraẹnisọrọ ati iwalaaye ti awọn lymphocytes B, ati aibikita ṣe idiwọ iṣẹ ṣiṣe ti BTK, ṣe idiwọ ilọsiwaju ati iwalaaye ti awọn sẹẹli tumo.Ni afikun, o gba ni kiakia lẹhin iṣakoso ẹnu, ifọkansi pilasima ti o pọju ti de 1 ~ 2h, ati awọn aati ikolu jẹ ipele 1 tabi 2, eyi ti yoo di aṣayan titun fun itọju CLL ati MCL.Ni Oṣu kọkanla ọjọ 13, Ọdun 2013, US FDA lati mu yara ile-iṣẹ Johnson & Johnson ti a fọwọsi ati Amẹrika Imbruvica (orukọ ti o wọpọ: Ibrutinib) fun itọju ti lymphoma cell mantle (MCL).Ibrutinib, ni a funni ni ipo Itọju ailera ni ilọsiwaju nipasẹ FDA ni Kínní 2013 ati pe o fọwọsi fun MCL ni Oṣu kọkanla ọjọ 13, ọdun 2013 ati CLL ni Oṣu Keji ọjọ 12, Ọdun 2014, lẹsẹsẹ.